AI's potential to revolutionize clinical trials and the pharmaceutical industry is gaining attention, with experts highlighting its ability to accelerate drug development, according to Time. While AI has shown promise in drug discovery, the bottleneck in bringing new medicines to patients lies in the lengthy and costly process of clinical trials, which can take years and cost hundreds of millions of dollars, according to Ben Liu, CEO of Formation Bio, an AI company in the biotech space.
Formation Bio, backed by high-profile investors, is working to address this challenge. The focus on clinical trials comes as the number of FDA-approved drugs has remained relatively constant at around 50 per year, despite the AI revolution, according to Time.
In other news, a Vox article discussed the impact of better-designed public housing on low-income children's future earnings, highlighting a surprising positive effect. The article, part of Vox's Future Perfect section, explored the history of public housing projects in the US, which rose in cities from the 1930s to 1960s.
Additional headlines this week, according to multiple sources, include American athletes preparing for the Milano Cortina Winter Olympics, with a focus on sleep quality and recovery. Cross-country skier Jessie Diggins is preparing for her final Olympic games, aiming for a historic individual gold medal. HBO's "Industry" season four will focus on a fraudulent fintech company facing regulatory challenges, while a new Peacock series, inspired by "The Burbs," explores themes of racial tension and suburban anxieties through the lens of a Black mother navigating a predominantly white neighborhood.
Discussion
AI Experts & Community
Be the first to comment